Recent Updates — ZYME
Zymeworks Inc. entered into a global exclusive license and collaboration agreement with F. Hoffmann-La Roche Ltd for its trispecific T-cell engager candidate ZW209, targeting DLL3-expressing tumors. Under the deal, Zymeworks receives a $55 million non-refundable upfront payment upon HSR clearance and a $40 million milestone upon Phase 1b initiation, with potential additional payments of up to $718 million based on development and commercial success. Roche will fund the ongoing Phase 1a trial and assume responsibility for subsequent global development and commercialization, while Zymeworks retains ownership of its underlying platform intellectual property. The transaction is subject to antitrust clearance. Zymeworks Inc. operates as a biotechnology company developing novel biotherapeutics and managing a portfolio of licensed healthcare assets.
On August 25, 2026, Zymeworks Inc. announced that partner Jazz Pharmaceuticals received FDA approval for two Ziihera (zanidatamab-hrii) regimens for first-line treatment of HER2-positive gastroesophageal adenocarcinoma. This regulatory milestone triggered a $250 million payment to Zymeworks, bringing total upfront and milestone payments from Jazz to $650 million. The company remains eligible for up to $1.3 billion in additional regulatory and commercial milestones plus tiered royalties of 10% to 20% on net sales. Zymeworks is a biotechnology company managing licensed healthcare assets and developing novel multifunctional biotherapeutics.
Zymeworks Inc. reported second quarter 2026 financial results with total revenue of $4.6 million and a net loss of $45.0 million, compared to $48.7 million in revenue and a $2.3 million net income in the prior year period. The company holds $322.5 million in cash resources as of June 30, 2026. Key developments include an August 25, 2026 U.S. PDUFA target action date for zanidatamab, which carries a potential $250 million approval milestone, and the expected closing of the Theravance Biopharma acquisition in the second half of 2026 to diversify revenue streams. Additionally, Zymeworks repurchased $49.4 million of common shares under its current program. The company operates as a biotechnology firm managing licensed healthcare assets and developing biotherapeutics.
Zymeworks Inc. entered into a merger agreement with Theravance Biopharma, Inc. to acquire it as a wholly owned subsidiary. Shareholders of Theravance will receive $17.00 in cash per share and one contingent value right (CVR) per share. The transaction is expected to close in the second half of 2026 and is being financed through a combination of cash on hand and $350 million in senior secured notes. Zymeworks is a biotechnology company focused on developing biopharmaceutical products.